Positive results with new oral microbiome drug for C. diff

Finch Therapeutics announced positive topline results from a randomized controlled trial of CP101 for the prevention of recurrent Clostridioides difficile infection, according to a press release.In PRISM3, a multicenter, randomized, double-blind, placebo-controlled phase 2 trial, researchers assessed the investigational oral microbiome drug CP101 in 206 patients with recurrent C. difficile at 51 sites across the…

EoE disease activity rapidly recurs with topical steroids

After an initial histologic response to topical steroids such as oral viscous budesonide or fluticasone from a multidose inhaler, researchers saw a rapid recurrence in eosinophilic esophagitis disease activity, according to results published in Clinical Gastroenterology and Hepatology.“Because most subjects had recurrent endoscopic and histologic signs not reliably detected by symptoms, maintenance therapy should be…

Typhoid fever, paratyphoid fever and the emergence of XDR typhoid fever

Typhoid fever and paratyphoid fever are clinically indistinguishable and produce the syndrome known as enteric fever. Both are caused by Salmonella that infect only humans. Therefore, when the diagnosis of typhoid or paratyphoid fever is made, the origin is another human.Paratyphoid fever is generally less severe than typhoid fever. The cause of typhoid fever is…

Federal government launches pilot program to crack down on illegal online opioid sales

HHS and the Commerce Department recently announced a new pilot program the agencies said could decrease the number of illegal opioids sold online.The program calls for the FDA to notify the internet registries Neustar, Verisign and the Public Interest Registry when operators of websites that sell unapproved opioids do not respond to FDA warnings “adequately…